Remote video URL
Your peers have not rated this talk yet.
2-minute watch | Talk 6 of 6

EBMT 2025

The quest continues

You Vs. R/R DLBCL: Navigating The Path To A Potential Cure.

Read more

Talks in this series

Interested in this topic?

Suggested for you

Explore suggested content tailored to your role within the CAR T-cell therapy journey

8-minute watch
FROM DATA TO DECISIONS: Improving patient outcomes for CAR T in DLBCL

Navigating life after CAR T, Part I: Patient experience and long-term well-being

Emily John

16-minute watch
FROM DATA TO DECISIONS: Improving patient outcomes for CAR T in DLBCL

Evolving strategies: Acute and long-term adverse event management

Dr Matthew Frank

18-minute watch
FROM DATA TO DECISIONS: Improving patient outcomes for CAR T in DLBCL

Building the foundation: Strategies to optimise patient outcomes

Dr Megan Melody

5-minute watch
FROM DATA TO DECISIONS: Improving patient outcomes for CAR T in DLBCL

Welcome and introduction

Prof. Karin Ekström Smedby

2-minute watch
DELIVERING OUTCOMES, NOT JUST CELLS: Why speed and reliability matter for CAR T patients

Conclusion and closing remarks

Dr Fredrik Schjesvold

18-minute watch
DELIVERING OUTCOMES, NOT JUST CELLS: Why speed and reliability matter for CAR T patients

From referral to recovery: Optimising the CAR T patient journey

Prof. Philippe Moreau

8-minute watch
DELIVERING OUTCOMES, NOT JUST CELLS: Why speed and reliability matter for CAR T patients

Speed and reliability: Shaping CAR T outcomes

Dr Fredrik Schjesvold

GFM-UNB-1778 November 2025
GFM-UNB-1778 November 2025

  This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.

Reporting of side effects 
If you get any side effects, talk to your doctor or nurse. In the United Kingdom, you can also report side effects directly via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. You can also report side effects and quality complaints to Gilead. For information now how to report a side effect in another country, click here. By reporting side effects, you can help provide more information on the safety of this medicine.

HCP Check with options

Select an option below that best describes your role to tailor the content you see:

Adverse events should be reported.
Healthcare professionals should report any adverse event via their national reporting systems. Reporting forms and information for your country of residence can be found here: https://www.gilead.com/utility/contact/report-an-adverse-event. For the UK, reporting forms and information can be found at www.mhra.gov.uk/yellowcard or via the Yellow Card app (download from the Apple App Store or Google Play Store). Adverse events should also be reported to Gilead to safety_FC@gilead.com or +44 (0) 1223 897500 or via https://public.gsir.gilead.com/.